NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)
Authors
McNamara, Mairead GSwain, J.
Craig, Z.
Sharma, R.
Faluyi, O. O.
Wadsley, J.
Morgan, C.
Wall, L. R.
Chau, I.
Reed, N.
Sarker, D.
Margetts, J.
Krell, D.
Cave, J.
Sharmila, S.
Anthoney, A.
Patel, A.
Lamarca, Angela
Hubner, Richard A
Valle, Juan W
Affiliation
University of Manchester, Manchester, United KingdomIssue Date
2022
Metadata
Show full item recordCitation
McNamara MG, Swain J, Craig Z, Sharma R, Faluyi OO, Wadsley J, et al. NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301173.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.4005Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4005Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.4005